Sodium 4‑phenylbutyrate inhibits protein glycation

  • Authors:
    • Kazuhiko Ono
    • Manabu Nakashima
  • View Affiliations

  • Published online on: October 15, 2020
  • Article Number: 61
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


The production and accumulation of advanced glycation end‑products (AGEs) are hypothesized to have a causal role in the development of the complications associated with aging and lifestyle‑related diseases, such as diabetes, atherosclerosis and hyperlipidemia. Therefore, it is important to reduce the production and accumulation of AGEs. In the present study, the ability of sodium 4‑phenylbutyrate (PBA) on inhibition of glycation was assessed. In vitro, PBA inhibited the glycation of albumin and collagen by up to 42.1 and 36.9%, respectively. Furthermore, when spontaneously diabetic KK mice were administered PBA (20 mg/day) or vehicle orally, glycosuria developed rapidly in the control mice, but after 6 weeks, only one treated mouse was glycosuric. In addition, the weight gain and HbA1c levels were significantly lower in the treated mice compared with the untreated mice (weight gain, 36.0 g vs. 39.4 g, P<0.01; HbA1C level, 3.96 vs. 4.78%, P<0.01; respectively). These results suggested that PBA also inhibited glycation in vivo. Further studies are required to determine whether PBA may be effective for the therapy or prevention of aging or lifestyle‑related diseases caused by the accumulation of AGEs. The method of administration and the side‑effects of PBA have already been established as PBA is already used clinically. Therefore, the repurposing of PBA for reducing AGE levels may be a potential option to reduce complications associated with aging.
View Figures
View References

Related Articles

Journal Cover

Volume 13 Issue 6

Print ISSN: 2049-9434
Online ISSN:2049-9442

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
Spandidos Publications style
Ono K and Ono K: Sodium 4‑phenylbutyrate inhibits protein glycation. Biomed Rep 13: 61, 2020
Ono, K., & Ono, K. (2020). Sodium 4‑phenylbutyrate inhibits protein glycation. Biomedical Reports, 13, 61.
Ono, K., Nakashima, M."Sodium 4‑phenylbutyrate inhibits protein glycation". Biomedical Reports 13.6 (2020): 61.
Ono, K., Nakashima, M."Sodium 4‑phenylbutyrate inhibits protein glycation". Biomedical Reports 13, no. 6 (2020): 61.